Could CABI fungi hold the key to new life-saving drugs?

[Guest guest]

Wouldn't these drugs be considered as " natural, herbal, alternative

remedies " that we have been informed or meant to believe by big

Pharma that they don't have any positive affect on human illnesses?

What a joke, even though we've known for many years that they are

continuing to research new plants, fungi, etc., in South America and

around the world for new medication. HMMMM, I guess they only work

if the pharmacutical companies put it out so they benefit.... I

will bite my tongue. They must really think the general public is

stupid.

KC

Could CABI fungi hold the key to new life-saving drugs?

Wednesday 13 June 2007

http://www.oxfordshirebioscience.com/obn_/news.php?

p=news_.tem & r=Z6HNXY4U4226

Oxfordshire Bioscience Network (press release) - Oxford,UK

for more information: http://www.cabi.org/datapage.asp?iDocID=657

Could CABI fungi hold the key to new life-saving drugs?

Scientists may be one step closer to finding new drugs to fight

MRSA, cancers and other diseases, after CABI, a leading bioservices

organisation announced that its fungal collection will be screened

by the University of Strathclyde.

CABI houses one of the world's largest genetic resource collections

of fungi, numbered at over 28,000 strains, including Fleming's

original penicillin producing isolate. They will be supplying the

University of Strathclyde's Institute for Drug Research (SIDR) with

extracts from filamentous fungi which will be screened to identify

pharmaceutically active compounds, which could potentially be

developed into drugs.

Joan Kelley, Executive Director Bioservices, CABI said:

" This is a really exciting collaboration and we are looking forward

to working with the expertise of the scientists at SIDR. We are

hopeful that our partnership will prove the winning formula for

discovering new pharmaceutical drugs to fight cancers, diseases and

resistant strains of infections such as MRSA. "

SIDR brings together scientists from different disciplines to focus

on drug discovery. They have developed test systems to detect

biological activity in samples of natural products that could lead

to new medicinal products. Previous work at SIDR found activities

from plant extracts against diabetes, obesity and psoriasis.

Professor Alan Harvey, Director of SIDR said:

" We are delighted to be working with CABI and to have access to

their fantastic source of fungal samples. We hope that this novel

source of chemical diversity will contain new compounds that can be

used to point the way to new drugs for serious diseases. "

Aspergillus flavus - a species of fungus found in CABI's collection.

CABI currently uses its fungal collection, along with the expertise

of its scientists to offer a range of services to businesses,

including fungal identification, sales, preservations, patenting,

training and consultancy. The partnership with SIDR will see CABI's

collection taken one step further, with the fungi being exploited

for natural products.

Although using biotechnology to develop new drugs is by no means

simple, the industry has seen steady success over the past few

years. Between 2000 and 2005, over 20 new drugs were released onto

the market originating from natural sources. And although this is

the first time SIDR has worked with fungal cultures, there are a

number of prescription drugs deriving from metabolites produced by

fungi that have been on the market for many years. These include

immunosuppressive agents, antibiotics such as penicillin, lipid

lowering agents and anti-fungal drugs.

ENDS

For all media enquires please contact Lynsey , PR and Corporate

Communications Manager, CABI on 01491 829 361 or email

l.clark@...

Editors notes:

About CABI

CABI is a not for profit organisation that improves people's lives

worldwide by providing information and applying scientific expertise

to solve problems in agriculture and the environment. Its mission

and direction is influenced by its 45 member countries who help

guide the activities undertaken as a business. These include

scientific publishing, projects and consultancy, information for

development and mycological services. CABI's activities contribute

directly to achieving Global Development Objectives, particularly

those concerned with poverty reduction, environmental sustainability

and partnership for development. For more information on CABI go to

www.cabi.org

About SIDR

The Strathclyde Institute for Drug Research identifies early-stage

commercial opportunities in drug research, develops them through

proof-of-principle stage, and seeks industrial partners for full

development. Since its creation in 1988, SIDR has had extensive

experience of working with pharmaceutical and biotech companies in

Europe, USA and Japan. SIDR provides industry with a portfolio of

drug discovery and drug delivery projects and a wealth of expertise

in drug research. Industrial collaborations are performed by

academic scientists with appropriate skills and experience. SIDR is

also working closely with the Strathclyde Institute for

Pharmaceutical and Biological Sciences, which this week announced a

new £35m centre to be created in Glasgow. For more information,

please visit www.strath.ac.uk

[Guest guest]

I JUST CANT WAIT FOR THE IDIOPATHIC VACCINE TO BE INTRODUCED FOR

CANCER. FUNNY HOW THEY CAN BE WORKING ON THIS WITHOUT KNOWING THE

CAUSE. HUMMM

>

> Wouldn't these drugs be considered as " natural, herbal, alternative

> remedies " that we have been informed or meant to believe by big

> Pharma that they don't have any positive affect on human illnesses?

> What a joke, even though we've known for many years that they are

> continuing to research new plants, fungi, etc., in South America

and

> around the world for new medication. HMMMM, I guess they only work

> if the pharmacutical companies put it out so they benefit.... I

> will bite my tongue. They must really think the general public is

> stupid.

>

> KC

>

>

>

> Could CABI fungi hold the key to new life-saving drugs?

>

> Wednesday 13 June 2007

>

> http://www.oxfordshirebioscience.com/obn_/news.php?

> p=news_.tem & r=Z6HNXY4U4226

>

> Oxfordshire Bioscience Network (press release) - Oxford,UK

>

>

>

> for more information: http://www.cabi.org/datapage.asp?iDocID=657

>

>

>

> Could CABI fungi hold the key to new life-saving drugs?

>

> Scientists may be one step closer to finding new drugs to fight

> MRSA, cancers and other diseases, after CABI, a leading bioservices

> organisation announced that its fungal collection will be screened

> by the University of Strathclyde.

>

> CABI houses one of the world's largest genetic resource collections

> of fungi, numbered at over 28,000 strains, including Fleming's

> original penicillin producing isolate. They will be supplying the

> University of Strathclyde's Institute for Drug Research (SIDR) with

> extracts from filamentous fungi which will be screened to identify

> pharmaceutically active compounds, which could potentially be

> developed into drugs.

>

> Joan Kelley, Executive Director Bioservices, CABI said:

>

> " This is a really exciting collaboration and we are looking forward

> to working with the expertise of the scientists at SIDR. We are

> hopeful that our partnership will prove the winning formula for

> discovering new pharmaceutical drugs to fight cancers, diseases and

> resistant strains of infections such as MRSA. "

>

> SIDR brings together scientists from different disciplines to focus

> on drug discovery. They have developed test systems to detect

> biological activity in samples of natural products that could lead

> to new medicinal products. Previous work at SIDR found activities

> from plant extracts against diabetes, obesity and psoriasis.

>

> Professor Alan Harvey, Director of SIDR said:

>

>

> " We are delighted to be working with CABI and to have access to

> their fantastic source of fungal samples. We hope that this novel

> source of chemical diversity will contain new compounds that can be

> used to point the way to new drugs for serious diseases. "

>

>

>

> Aspergillus flavus - a species of fungus found in CABI's

collection.

>

>

> CABI currently uses its fungal collection, along with the

expertise

> of its scientists to offer a range of services to businesses,

> including fungal identification, sales, preservations, patenting,

> training and consultancy. The partnership with SIDR will see

CABI's

> collection taken one step further, with the fungi being exploited

> for natural products.

>

>

> Although using biotechnology to develop new drugs is by no means

> simple, the industry has seen steady success over the past few

> years. Between 2000 and 2005, over 20 new drugs were released onto

> the market originating from natural sources. And although this is

> the first time SIDR has worked with fungal cultures, there are a

> number of prescription drugs deriving from metabolites produced by

> fungi that have been on the market for many years. These include

> immunosuppressive agents, antibiotics such as penicillin, lipid

> lowering agents and anti-fungal drugs.

>

>

>

>

> ENDS

>

> For all media enquires please contact Lynsey , PR and

Corporate

> Communications Manager, CABI on 01491 829 361 or email

> l.clark@...

>

> Editors notes:

>

> About CABI

>

> CABI is a not for profit organisation that improves people's lives

> worldwide by providing information and applying scientific

expertise

> to solve problems in agriculture and the environment. Its mission

> and direction is influenced by its 45 member countries who help

> guide the activities undertaken as a business. These include

> scientific publishing, projects and consultancy, information for

> development and mycological services. CABI's activities contribute

> directly to achieving Global Development Objectives, particularly

> those concerned with poverty reduction, environmental

sustainability

> and partnership for development. For more information on CABI go

to

> www.cabi.org

>

>

>

> About SIDR

>

> The Strathclyde Institute for Drug Research identifies early-stage

> commercial opportunities in drug research, develops them through

> proof-of-principle stage, and seeks industrial partners for full

> development. Since its creation in 1988, SIDR has had extensive

> experience of working with pharmaceutical and biotech companies in

> Europe, USA and Japan. SIDR provides industry with a portfolio of

> drug discovery and drug delivery projects and a wealth of expertise

> in drug research. Industrial collaborations are performed by

> academic scientists with appropriate skills and experience. SIDR is

> also working closely with the Strathclyde Institute for

> Pharmaceutical and Biological Sciences, which this week announced a

> new £35m centre to be created in Glasgow. For more information,

> please visit www.strath.ac.uk

>